Who are d-borneol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): sevoflurane-sufentanil balanced, Desflurane Inhalant Product, Remifentanil and Desflurane, Passiflora incarnata, All registered antiepileptic drugs, Methoxyflurane, MEOF.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/d-borneol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

d-borneol — Competitive Intelligence Brief

d-borneol (d-borneol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Pain relief, Inflammation.

phase 3 GABA receptor Pain relief, Inflammation Small molecule Live · refreshed every 30 min

Target snapshot

d-borneol (d-borneol) — Peking University Third Hospital. d-borneol is a natural compound that acts as a GABA receptor agonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
d-borneol TARGET	d-borneol	Peking University Third Hospital	phase 3		GABA receptor
sevoflurane-sufentanil balanced	sevoflurane-sufentanil balanced	Konkuk University Medical Center	marketed	Balanced anesthetic combination	GABA receptors (sevoflurane); mu-opioid receptors (sufentanil)
Desflurane Inhalant Product	Desflurane Inhalant Product	Sichuan Provincial People's Hospital	marketed	Volatile inhalational anesthetic	GABA receptors, NMDA receptors, potassium channels
Remifentanil and Desflurane	Remifentanil and Desflurane	The Cooper Health System	marketed	Opioid agonist and volatile anesthetic combination	Mu-opioid receptor (remifentanil); GABA receptors and ion channels (desflurane)
Passiflora incarnata	Passiflora incarnata	Nutricion Medica S.L.	marketed	Herbal anxiolytic/sedative	GABA receptors, serotonin receptors (non-selective)
All registered antiepileptic drugs	All registered antiepileptic drugs	UMC Utrecht	marketed	Antiepileptic drugs (heterogeneous class)	Multiple targets including voltage-gated sodium channels, GABA receptors, calcium channels, SV2A, and others depending on specific agent
Methoxyflurane, MEOF	Methoxyflurane, MEOF	Sunnybrook Health Sciences Centre	marketed	Volatile halogenated ether anesthetic	GABA receptors, NMDA receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). d-borneol — Competitive Intelligence Brief. https://druglandscape.com/ci/d-borneol. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab